Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Musculoskeletal  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location

Multiple Myeloma Clinical Trials

A listing of Multiple Myeloma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (244) clinical trials

People with multiple myeloma are asked to participate in a research study being conducted by Montefiore Medical Center

Phase N/A

This study will be conducted in 2 parts. The phase 1b part will be an international, phase 1b, open-label, dose-escalation assessment of radium-223 dichloride administered with bortezomib and dexamethasone in subjects with relapsed multiple myeloma. The primary endpoint is to determine the optimal dose of radium-223 dichloride in combination with ...

Phase

The purpose of this study is to compare the efficacy of daratumumab in combination with lenalidomide and dexamethasone to that of lenalidomide and dexamethasone in terms of progression-free survival (PFS) in participants with newly diagnosed multiple myeloma (a blood cancer of plasma cells) who are not candidates for high dose ...

Phase

Solid tumor, lymphoma or multiple myeloma with measurable disease and progression following at least 1st line treatment.

Phase N/A

Tacrolimus and MMF as Post Grafting Immunosuppression After Conditioning With Flu TBI for HLA Matched Family Donor

Conditioning regimen: 1. Days - 4 to -2: Fludarabine 30 mg/m2/day IV. 2. Day 0: TBI 2.0 Gy at 6-7 cGy/min from a linear accelerator, followed by stem-cell infusion. TBI will preferably be administered between 7:00 a.m. and 1:00 p.m. to avoid proximity to tacrolimus/MMF administration. Immunosuppression: Day -3: Start ...

Phase

Myeloablative Umbilical Cord Blood Transplantation in Hematological Diseases

OBJECTIVES: Primary - Determine the 1-year survival of patients undergoing unrelated umbilical cord blood transplantation (UCBT) for hematologic malignancies treated with myeloablative preparative regimen comprising fludarabine, cyclophosphamide, and fractionated total-body irradiation. Secondary - Determine the incidence of transplant-related mortality at 6 months after UCBT. - Evaluate the pattern of chimerism ...

Phase

VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)

Protocol DSMM VIII is a multi-center, open-label study evaluating the safety and tolerability, as well as the efficacy, of maintenance treatment with VELCADE in patients with multiple myeloma with detectable disease activity following tandem high-dose chemotherapy and autologous SCT. The time from SCT to the initiation of VELCADE treatment will ...

Phase

PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma

Although the overall survival was improved with the introduction of high dose therapy with autologous hematopoetic stem cell transplantation,it remains as a incurable disease. Most patients ultimately relapse. Recenlty, targeted therapy using novel agents, such as bortezomib and thalidomide, shows the possibility of improved in this situation. Among them, PAD ...

Phase

Non-Myeloablative Allogeneic Transplantation From Unrelated Donors in Multiple Myeloma

Primary end points are engraftment and non-relapse mortality. Secondary end points are disease response, overall survival, progression and event free survivals. Patient eligibility criteria. Inclusion criteria included: - Diagnosis of Durie-Salmon stage IIA-IIIB multiple myeloma - Age > 18 and ≤ 65 years at the start of the donor search ...

Phase

Doxorubicin Hydrochloride Liposome Melphalan and Bortezomib in Treating Patients With Relapsed or Refractory Stage I Stage II or Stage III Multiple Myeloma

OBJECTIVES: Primary - Determine the safety and tolerability of doxorubicin HCl liposome, melphalan, and bortezomib in patients with relapsed or refractory stage I-III multiple myeloma. - Determine the maximum tolerated dose (MTD) of this regimen in these patients. Secondary - Determine the overall response rate, including complete, near-complete, partial, and ...

Phase